Methylene blue and pregnancy: what the safety data shows

Last updated 2026-07-30

Is methylene blue safe to take during pregnancy?

No, not for the reasons most people are taking it. Methylene blue is FDA-approved as a prescription injectable drug for acquired methemoglobinemia, a blood disorder where hemoglobin can't release oxygen properly ^[1]. Outside that emergency use, there's no approved indication, and there's certainly no pregnancy safety data for the oral capsules or drops people take hoping for more energy, sharper focus, or slower aging. The clinical literature on methylene blue in pregnancy comes almost entirely from a specific historical use: injecting it directly into the amniotic sac (intra-amniotic injection) as a dye marker during procedures on twin pregnancies, back in the 1990s and earlier. That research is where the real fetal harm signals showed up, and it's the main reason obstetric guidance treats this drug with real caution. If you are pregnant, trying to conceive, or breastfeeding, the honest answer is to skip methylene blue entirely unless a physician is using it to treat a diagnosed condition like methemoglobinemia and has weighed that risk against the alternative. Nobody is publishing trials on methylene blue as a longevity or nootropic supplement in pregnant women, and nobody should expect that data to appear.

Does methylene blue cross the placenta?

Yes. Methylene blue is a small, lipophilic molecule, and drugs with that profile generally cross the placental barrier readily. That's exactly why it was historically injected into the amniotic fluid in twin pregnancies undergoing amniocentesis, to let physicians visually track which sac fluid was being withdrawn during a second tap. The dye doesn't stay isolated in the fluid; it gets absorbed by the fetus. Case reports from that era documented fetal methemoglobinemia and hemolytic anemia in babies exposed to intra-amniotic methylene blue, along with a cluster of reports linking it to jejunal or ileal atresia (a birth defect where part of the small intestine fails to form a normal channel) ^[2][3]. A widely cited case series in the American Journal of Obstetrics and Gynecology described this pattern of intestinal atresia following intra-amniotic methylene blue use in twin pregnancies, and it's part of why the procedure fell out of favor ^[3]. That's not the same exposure route or dose as an oral capsule taken by the mother, and nobody has run a controlled study comparing the two. But the placental crossing itself isn't in question. If the drug gets into fetal circulation from a direct amniotic injection, an oral dose that circulates in maternal blood is going to reach the fetus too.

What does the FDA label say about methylene blue and pregnancy?

The prescribing information for injectable methylene blue (marketed as Provayblue and generics) carries specific warnings tied to fetal risk from historical intra-amniotic use, and it flags methylene blue's MAOI activity as a serotonin syndrome risk when combined with serotonergic drugs ^[1]. Prescribing physicians are directed to weigh the mother's medical need for methemoglobinemia treatment against these documented risks. Methemoglobinemia itself can be life-threatening. If a pregnant patient develops it (from an overdose of certain drugs, nitrites, or other oxidizing agents) a physician may still choose to give methylene blue because the alternative, untreated methemoglobinemia, is more dangerous. That's a real clinical judgment call made in a hospital, not a decision a supplement user is making at home. That distinction matters enormously. FDA approval for methemoglobinemia treatment is not an endorsement of oral methylene blue as a wellness supplement, and it's definitely not a green light for pregnant women managing normal energy or focus concerns.

Can methylene blue cause birth defects or miscarriage?

The strongest human signal comes from the intestinal atresia case reports tied to intra-amniotic injection, not oral supplement use. A case series published in the early 1990s and later reviews described intestinal atresia in infants whose mothers underwent intra-amniotic methylene blue injection during twin amniocentesis, and this association was consistent enough across multiple reports that the practice was largely abandoned ^[2][3]. Separately, fetal methemoglobinemia and hemolytic anemia have been reported in newborns after this same exposure route, presumably because methylene blue at high local concentrations oxidizes fetal hemoglobin in a fetus whose enzyme systems for reducing it back are still immature ^[2]. There is no published human trial data on miscarriage risk, birth defect risk, or developmental outcomes from oral methylene blue taken by pregnant women at nootropic or longevity doses (commonly discussed in the 0.5 mg/kg to low single-digit mg/kg range in other contexts). That absence of data is not reassurance. It means nobody has looked, and the closest analogous human data we have (the intra-amniotic case reports) point toward real fetal risk from a related exposure. Treat that as a reason for caution, not a technicality to argue around.

Is methylene blue safe while breastfeeding?

There isn't good published data here either, and the honest answer is nobody knows the transfer rate into human milk at supplement doses. Methylene blue is a small molecule that's excreted partly in urine and partly through bile, and drugs with that profile often do pass into breast milk to some degree. Given the MAOI activity, the G6PD-related hemolysis risk in a nursing infant, and the total absence of infant safety data, the reasonable clinical stance is to avoid it while breastfeeding unless a physician has a specific medical reason to use it and has considered pausing breastfeeding during that treatment window. This is the same conservative logic obstetric and neonatal guidance applies to most drugs lacking lactation safety studies: no data does not mean safe.

Why is methylene blue an MAOI risk, and does that matter more during pregnancy?

Methylene blue inhibits monoamine oxidase A, the enzyme that breaks down serotonin. That's a documented pharmacologic property, not a fringe claim, and it's exactly why the FDA label carries a serotonin syndrome warning for patients on SSRIs, SNRIs, or other serotonergic drugs ^[1]. Serotonin syndrome can cause agitation, high fever, rapid heart rate, and in severe cases seizures or death. Pregnancy doesn't change the underlying pharmacology, but it raises the stakes. A lot of pregnant and postpartum women are on SSRIs like sertraline for depression or anxiety, and this is one of the most common medication classes prescribed in that population. Combining methylene blue with any of these drugs, pregnant or not, is dangerous and is explicitly warned against in the drug's labeling. If you're on an antidepressant, this alone is a hard stop for methylene blue regardless of pregnancy status. If you take methylene blue for a legitimate medical emergency while pregnant and on an SSRI, that has to be a hospital decision with the serotonergic drug held or managed, not something to attempt outside supervised care.

What about G6PD deficiency and pregnancy?

G6PD deficiency is a genuine, well-established contraindication for methylene blue, pregnant or not. Methylene blue relies on a functioning G6PD enzyme pathway to get reduced back into its active leucomethylene blue form; in patients who lack that enzyme, it can trigger severe hemolytic anemia instead of treating methemoglobinemia ^[1]. G6PD deficiency is X-linked and more common in people of African, Mediterranean, Middle Eastern, and Southeast Asian ancestry. It's also relevant to the fetus and newborn independent of the mother's own status, since G6PD deficiency can be inherited by the baby. If a mother is a known G6PD carrier or the family history is unclear, that's another reason methylene blue exposure during pregnancy needs a physician's involvement, not self-directed supplement use. Anyone considering methylene blue for any reason, pregnancy or not, should know their G6PD status first. This is a case where a simple blood test genuinely changes the risk calculus.

Is pharmaceutical-grade methylene blue different from what's sold as a supplement?

Yes, and this distinction is not marketing noise. Pharmaceutical-grade methylene blue meets USP (United States Pharmacopeia) purity standards and is manufactured under FDA-regulated conditions for the injectable drug product ^[1]. Aquarium-grade or industrial-grade methylene blue, sold cheaply for fish tank treatment or as a lab dye, is not held to that purity standard and can contain heavy metal contaminants or other impurities not meant for ingestion. This matters more, not less, during pregnancy. A contaminated product adds an unpredictable toxic exposure on top of methylene blue's own known risks, at exactly the time when the developing fetus has the least tolerance for unregulated exposures. If a pregnant reader is going to have any conversation with a doctor about methylene blue at all, that conversation needs to specify pharmaceutical-grade, USP-verified product only, and honestly, in pregnancy the better answer is usually not to have that conversation lead anywhere near actual use. Outside of pregnancy, people researching methylene blue for energy or focus should still care about this distinction; you can read more about how the evidence for those uses stacks up in our methylene blue reviews piece and our breakdown of methylene blue pros and cons.

What if I took methylene blue before I knew I was pregnant?

Call your OB or midwife and tell them exactly what you took, how much, and when. This isn't a situation to research alone or panic over silently, but it's also not something to guess about. Your care team can look at the dose, the timing relative to your pregnancy, and your G6PD and medication history, and give you actual guidance rather than a generic internet answer. There is no established human data quantifying risk from a single or short-term oral exposure at typical supplement doses (commonly discussed in ranges like 0.5 to 4 mg/kg in non-pregnant contexts) taken before pregnancy was known. The documented harms in the literature come from intentional, repeated, direct intra-amniotic dosing in already-established pregnancies, a very different exposure. That's a reason for calm, not for assuming there's zero risk. Bring it to your doctor and let them make the call with your full history in front of them.

Are the energy, focus, and anti-aging claims about methylene blue backed by real evidence?

Some of it, in narrow, mostly non-pregnant, non-human contexts. Methylene blue is studied as a mitochondrial electron transport agent and has shown effects on memory and mitochondrial function in preclinical studies, and there are small human trials looking at cognitive effects at low doses ^[4]. None of this research includes pregnant participants, and none of it is designed to establish pregnancy safety. The honest framing: methylene blue's approved use is methemoglobinemia treatment. The nootropic, mitochondrial, and anti-aging uses people are drawn to are off-label, rest on preclinical or small human studies, and have not been evaluated by FDA for those purposes at all. That gap between approved use and popular use is exactly where pregnancy safety data disappears, because nobody is running trials in pregnant women for an off-label use. If you're weighing whether methylene blue is worth using at all outside pregnancy, our is methylene blue worth it piece and methylene blue results timeline article walk through what the actual evidence supports and how fast (or not) people report noticing anything.

What should I do if I want to try methylene blue after pregnancy or while planning to conceive?

Wait until you've talked to a physician who knows your full history, including G6PD status, current medications (especially any SSRI, SNRI, MAOI, or other serotonergic drug), and whether you're currently breastfeeding. This isn't a supplement to start casually during a preconception window given the total lack of reproductive safety data. If, after that conversation, you and a provider decide there's a reasonable off-label case for trying it once you're clearly not pregnant or nursing, sourcing matters. Methylene Blue Bio's provider-reviewed model connects people with clinicians who screen for exactly these contraindications (G6PD status, serotonergic medications, pregnancy and breastfeeding status) before any prescription moves forward, with fulfillment handled through a licensed pharmacy partner rather than an unregulated supplement seller. That's a meaningfully different path than buying loose powder online with no grade verification and no medical screening at all. For anyone still deciding whether it's worth pursuing at all, our methylene blue before and after and methylene blue success rate pieces cover what real users and the available data actually show, separate from the pregnancy question.

Frequently asked questions

Can you take methylene blue while pregnant for energy or focus?

No. There's no human safety data for methylene blue at nootropic doses in pregnancy, and the closest related human data, from intra-amniotic use, shows real fetal risk including hemolytic anemia and intestinal atresia in case reports. Energy and focus are not medical emergencies that would justify that unknown risk.

Does methylene blue cause birth defects?

Case series link intra-amniotic methylene blue injection (a now largely abandoned procedure) to intestinal atresia in infants, first reported in the early 1990s. There's no equivalent human data for oral supplement doses, but the absence of data isn't the same as evidence of safety.

Is methylene blue an MAOI, and why does that matter in pregnancy?

Yes, methylene blue inhibits monoamine oxidase A and carries an FDA label warning for serotonin syndrome risk when combined with SSRIs, SNRIs, or other serotonergic drugs. Many pregnant and postpartum women take SSRIs for depression or anxiety, making this interaction especially relevant to screen for.

Can methylene blue cause miscarriage?

There's no published human data directly linking oral methylene blue supplement use to miscarriage. The known fetal risks in the literature come from direct intra-amniotic injection in twin pregnancies, a different exposure route, but that data is still the closest human signal we have, and it points toward caution.

Is it safe to take methylene blue while breastfeeding?

There's no published data on how much methylene blue transfers into human breast milk. Given its MAOI activity and G6PD-related hemolysis risk, the conservative and medically sound approach is to avoid it while nursing unless a physician has a specific treatment reason and manages that decision directly.

What is methylene blue actually FDA-approved to treat?

Methylene blue injection is FDA-approved to treat acquired methemoglobinemia, a condition where hemoglobin can't carry oxygen normally. It is not FDA-approved for energy, focus, mitochondrial support, or anti-aging use; those applications are off-label and rest on small or preclinical studies.

Does G6PD deficiency matter more during pregnancy?

G6PD deficiency is a contraindication for methylene blue regardless of pregnancy status, since it can trigger severe hemolytic anemia instead of resolving methemoglobinemia. It matters extra in pregnancy because G6PD deficiency is X-linked and can be inherited by the fetus, adding a second person's risk to consider.

What's the difference between pharmaceutical-grade and aquarium-grade methylene blue?

Pharmaceutical-grade methylene blue meets USP purity standards under FDA-regulated manufacturing. Aquarium or industrial-grade versions are not held to that standard and can carry heavy metal or other contaminants. This distinction is dangerous to ignore generally, and especially risky during pregnancy when contaminant tolerance is lowest.

I took methylene blue before I found out I was pregnant. What should I do?

Contact your OB or midwife immediately and tell them what you took, how much, and when. There's no established human data quantifying risk from a brief early exposure, but your care team can review your specific dose, timing, and medical history rather than you guessing from general information.

Can methylene blue cross the placenta?

Yes. Methylene blue is a small, lipophilic molecule that crosses the placental barrier, which is exactly why it was historically used as a dye marker injected directly into the amniotic sac during twin pregnancy amniocentesis, before that procedure fell out of favor due to documented fetal harm.

Are there any situations where a pregnant woman would be given methylene blue?

Yes, if she develops methemoglobinemia, a serious blood disorder, from drug toxicity or another cause. In that scenario a physician may judge that treating the emergency outweighs the documented fetal risks, but that's a supervised hospital decision, not a self-directed supplement choice.

Does methylene blue interact with prenatal vitamins or other supplements?

There's no specific documented interaction with standard prenatal vitamins. The interaction that actually matters is with serotonergic drugs (SSRIs, SNRIs, certain migraine and pain medications) due to methylene blue's MAOI activity, which is a far more urgent concern than vitamin interactions during pregnancy.

Sources

1. FDA, Provayblue (methylene blue injection) prescribing information: FDA approval for methemoglobinemia, MAOI/serotonin syndrome warning, G6PD contraindication, and pregnancy risk warnings
2. Cragan JD, "Teratogen update: methylene blue," Teratology, 1999, PMID 10441825: fetal hemolytic anemia and methemoglobinemia reported after intra-amniotic methylene blue injection
3. Nicolini U, Monni G, "Intestinal obstruction in babies exposed in utero to methylene blue," Lancet, 1990, PMID 1970034: case reports linking intra-amniotic methylene blue injection to intestinal (jejunal/ileal) atresia in infants
4. Rodriguez P et al., "Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain," Radiology, 2014, PMID 24475841: low-dose methylene blue studied for cognitive and brain metabolic effects in a small human trial
5. Oz M, Lorke DE, Hasan M, Petroianu GA, "Cellular and molecular actions of methylene blue in the nervous system," Medicinal Research Reviews, 2011, PMID 19645031: methylene blue's mechanism as a mitochondrial electron transport / redox agent underlying its studied cognitive and neuroprotective effects